First In Human Study Evaluating the Safety and Performance of the "LapBox" Containment System for Laparoscopic Tissue Morcellation

NCT ID: NCT04231812

Last Updated: 2020-01-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-25
• Study Completion Date: 2020-05-01

Brief Summary

Study to assess the safety, and performance of the LapBox in patients in terms of duration of deployment, organ insertion into the "LapBox" bag, ease of use, success of containment and performance.

Detailed Description

The LapBox is intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy Ten (10) adult female patients, scheduled for the laparoscopic gynecological procedure, with up to 700gr mass to be removed and with no suspicion of malignancy.

Patients scheduled for elective laparoscopic hysterectomy, myomectomy or removal of an adnexal mass where either manual morcellation or power morcellation is needed for tissue will be enrolled. Each patient will be required to participate in 3 visits:

Visit 1: Screening and Enrollment, as part of the pre-operative visit and confirmation of compliance. Such a visit can be more than 1 day.

Visit 2: Laparoscopic organ removal procedure- morcellation utilizing LapBox containment system.

Visit 3:up appointment up to 7 weeks (7 days) post-procedure.

During visit 2 (laparoscopic organ removal procedure), the following steps will be performed:

• Following tissue harvest and prior to morcellation, a peritoneal wash sample will be obtained for a cytology evaluation.
• The LapBox will then be inserted to the patient abdomen through the abdominal wall and deployed.
• The harvested tissue will be inserted into the LapBox using standard technique.
• The LapBox opening will be extracted outside the abdomen.
• Depending on the type of morcellation (power or mechanical), the incision may be extended as needed.
• The appropriate type of port will be placed.

Power morcellation:

• The morcellator will be inserted.
• The laparoscope will be placed inside the bag and provide visualization of the procedure. Alternatively, direct visualization may be utilized.
• The morcellator will be operated in a standardized fashion. Manual morcellation will be performed as per standard practice.
• The LapBox will be removed through the abdominal opening. A second peritoneal wash sample will be obtained for a cytology evaluation in order to compare pre and post morcellation findings.

Following the procedure, tissue weight will be recorded, and leakage testing will be performed on used devices.

Conditions

Laparoscopic Surgical Procedure

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DEVICE_FEASIBILITY
• Blinding Strategy: NONE

Study Groups

open lable

Prospective, open-label

Group Type: OTHER

Laparoscopic Tissue Morcellation working space (bag)

Intervention Type: DEVICE

The "LapBox" is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy

Interventions

Laparoscopic Tissue Morcellation working space (bag)

The "LapBox" is working space (bag) intended for use as a laparoscopic instrument port and tissue containment system that creates a working space allowing for visualization during power or manual morcellation procedure following a laparoscopic procedure for the excision of benign gynecologic tissue that is not suspected to contain malignancy

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Female patients indicated for elective surgery requiring laparoscopic hysterectomy, myomectomy where either manual morcellation or power morcellation is needed for tissue removal at which a morcellator for cutting and extraction of tissue is required.

2. Pre- menopausal woman patient age 18-50 years

3. Mass measured with diameter up to 10 cm to be removed

4. Normal Pap test result within the last 24 months prior to enrollment

5. Normal and /or Non-Clinically Significant as per investigator discretion CBC and Blood chemistry test within at least 6 months prior to surgery.

6. Signed an informed consent

Exclusion Criteria

1. Emergency cases

2. Abdominal wall thickness is greater than 10 cm according to US measurements.

3. Patient requires procedure involving the ovaries (e.g., Oophorectomy, Salpingo)

4. Patient is defined as a "high risk" patient for developing cancer (per standard assessment, including but not limited to imaging)

5. Suspicion of malignant or pre-malignant tissue according to preoperative assessment including US exam within 30 days prior to surgery

6. Known or suspected gynecologic malignancy within the past five years

7. Pacemaker, internal defibrillator/cardio converter

8. Previous extensive pelvic surgery or any other medical procedure which in the investigator's judgment contraindicates the patient's participation

9. Contraindications to anesthesia or abdominal surgery. ASA score above 3

10. Concurrent participation in any other clinical study

11. Active infection at the time of the procedure.

12. BMI<20 or BMI>40

13. Known history or presence of any medical disorder, which in the investigator's judgment contraindicates the patient's participation (e.g., Known and documented active liver disease, renal failure, cognitive disorder, cardiopulmonary disease, impaired coagulation parameters, etc.)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

ARKSurgical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Roy Mashiach, Dr

Role: PRINCIPAL_INVESTIGATOR

Assuta Tel Aviv Medical Center, Tel Aviv, Israel

Yuval Kaufman, Dr

Role: PRINCIPAL_INVESTIGATOR

Assuta Haifa Medical Center, Haifa, Israel

Central Contacts

Stav Tori

Role: CONTACT

stav@ark-surgical.com

972523594441

Ilana Fishman

Role: CONTACT

ilana@endpoint.co.il

972547545065

Other Identifiers

ARK-001

Identifier Type: -

Identifier Source: org_study_id